carbidopa การใช้

Droxidopa can be coupled with a peripheral aromatic L-amino acid decarboxylase inhibitor ( AAADI ) or DOPA decarboxylase inhibitor ( DDC ) such as carbidopa ( Lodosyn ) to increase central norepinephrine concentrations while minimizing increases of peripheral levels.
It is often co-administered with an enzyme inhibitor of peripheral decarboxylation such as carbidopa or benserazide, to reduce the amount converted to dopamine in the periphery and thereby increase the amount of L-DOPA that enters the brain.
In fact, one of the primary conditions that can result from GTPCH-related BH4 deficiency is dopamine-responsive dystonia; currently, this condition is typically treated with carbidopa / levodopa, which directly restores dopamine levels within the brain.
Several cases of scleroderma-like illness have been reported in patients using carbidopa and 5-HTP . In Europe, 5-HTP is prescribed with carbidopa to prevent the conversion of 5-HTP into serotonin until it reaches the brain.
Several cases of scleroderma-like illness have been reported in patients using carbidopa and 5-HTP . In Europe, 5-HTP is prescribed with carbidopa to prevent the conversion of 5-HTP into serotonin until it reaches the brain.